Biogen fends off Mylan’s challenge to patent on top-selling multiple sclerosis drug
The Patent Trial and Appeal Board ruled against the generic drugmaker's inter partes review seeking to overturn the patent covering Tecfidera. The drug, which had $4.4 billion in sales last year, could remain protected through February 2028.